Cowen upgraded GenMark Diagnostics (Nasdaq: GNMK) from a Market Perform rating to an Outperform rating and lifted its price target from $10 to $17 sending the stock price soaring $1.79 to close at $10.61.
GenMark Diagnostics upgraded
September 16, 2016 at 18:57 PM EDT